Centro de Investigaciones Bioclínicas de la Fundación Fader Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2007
NCT00537953
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

antimony (1 trial)

miltefosine (impavido) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leishmaniasis (Phase 2)

Leishmaniasis, Cutaneous (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2